Which medication is recognized as a breakthrough treatment for acute migraines?

Lasmiditan is recognized as a breakthrough treatment for acute migraines due to its unique mechanism of action as a selective serotonin 5-HT1F receptor agonist. Unlike traditional treatments that primarily target 5-HT1B and 5-HT1D receptors, lasmiditan provides a novel approach without causing vasoconstriction, making it particularly valuable for patients who may be at risk for cardiovascular issues or who do not respond to other migraine treatments. This innovative action can effectively relieve migraine symptoms and has shown promise in clinical trials, leading to its classification as a breakthrough therapy.

Other options, while commonly used for migraine treatment, do not embody the same level of innovation or differentiation as lasmiditan. For example, ibuprofen and ketorolac are NSAIDs that help manage pain and inflammation, but they do not target the pathophysiology of migraines specifically. Sumatriptan, on the other hand, is a triptan that acts on the same receptors as lasmiditan, but it can cause vasoconstriction, which limits its use in certain patients. Thus, lasmiditan stands out as a significant advancement in the acute management of migraines.